Internet Archive Scholar

COVID-19 in patients with IBD and pancreaticobiliary disorders

Sara El Ouali, Jessica Philpott, John Vargo, Miguel Regueiro
2020 Cleveland Clinic journal of medicine  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (134.5 kB)
https://web.archive.org/web/20200901102033/https://www.ccjm.org/content/ccjom/early/2020/08/25/ccjm.87a.ccc062.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

Evidence shows that COVID-19 can exacerbate symptoms of inflammatory bowel disease (IBD) and pancreaticobiliary disorders, and it is important to distinguish between an IBD exacerbation and symptoms caused by COVID-19. Although IBD does not appear to increase the risk for COVID-19 or worsen outcomes, corticosteroids can increase the risk and should be avoided when treating these patients. Pancreatic and biliary disease have been described in patients with COVID-19, but it is not clear whether
more » ... VID-19 induces these diseases. For facilities resuming endoscopic procedures, there are consensus guidelines for minimizing the COVID-19 transmission risks with these procedures.
doi:10.3949/ccjm.87a.ccc062 pmid:32855178 fatcat:vrta7jhdmbfrpeockrbhytv7cu
Open Access
Citation

Sara El Ouali, Jessica Philpott, John Vargo, Miguel Regueiro. "COVID-19 in patients with IBD and pancreaticobiliary disorders." Cleveland Clinic journal of medicine (2020)